Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness - Unité de Spectrométrie de Masse Biologique et Protéomique Access content directly
Journal Articles Medicinal Research Reviews Year : 2021

Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness

Tania Gamberi
  • Function : Author
Tania Fiaschi
  • Function : Author
Alessandra Modesti
  • Function : Author
Flavia Sorbi
  • Function : Author
Francesca Magherini
  • Function : Author
  • PersonId : 1139564

Abstract

Auranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several Med Res Rev.
Fichier principal
Vignette du fichier
med.21872.pdf (1.85 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-03461453 , version 1 (01-12-2021)

Identifiers

Cite

Tania Gamberi, Giovanni Chiappetta, Tania Fiaschi, Alessandra Modesti, Flavia Sorbi, et al.. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. Medicinal Research Reviews, 2021, ⟨10.1002/med.21872⟩. ⟨hal-03461453⟩
37 View
90 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More